Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.57 |
| ▸ | GAA | P10253 | 6/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.57 |
| ▸ | HPGD | P15428 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | CFTR | P13569 | 3/20 | 0.51 |
| ▸ | GLA | P06280 | 2/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | CISD2 | Q8N5K1 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21798988 | 0.88 | KDM4E (0.51) | ALDH1A1KDM4EGAAHSD17B10HPGD | |
| SCHEMBL1891146 | 0.87 | ALDH1A1 (0.60) | ALDH1A1KDM4EGAAHSD17B10HPGD | |
| SCHEMBL11520744 | 0.84 | CA12 (0.46) | ALDH1A1KDM4EGAAHSD17B10HPGD | |
| SCHEMBL21798992 | 0.84 | XDH (0.50) | ALDH1A1KDM4EGAAHSD17B10HPGD | |
| SCHEMBL18095098 | 0.83 | ALDH1A1 (0.57) | ALDH1A1KDM4EGAAHSD17B10HPGD | |
| SCHEMBL15639611 | 0.83 | ALDH1A1 (0.55) | ALDH1A1KDM4EGAAHSD17B10MAPT | |
| SCHEMBL6353385 | 0.83 | ABCB1 (0.39) | ALDH1A1KDM4EGAAHSD17B10HPGD | |
| SCHEMBL546514 | 0.81 | CA12 (0.61) | GAATSHRNAMPTPTPN11 | |
| SCHEMBL1321345 | 0.81 | ALDH1A1 (0.44) | ALDH1A1KDM4EGAAHPGDCISD2 | |
| SCHEMBL4314458 | 0.81 | NAMPT (0.41) | ALDH1A1KDM4EGAAHSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4536643-A1 | BENZOPYRIMIDIN-4(3H)-ONES AS PI3K INHIBITORS | OnKure, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| CN-119744260-A | Benzopyrimidin-4 (3H) -ones as PI3K inhibitors | 恩库勒公司 | 2025-04-01 | — | — | CN | disclosed |
| US-20250026769-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2025-01-23 | — | — | US | disclosed |
| EP-4423081-A2 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | The Children's Medical Center Corporation (US) | 2024-09-04 | — | — | EP | disclosed |
| US-12065421-B2 | Inhibitors of oplophorus luciferase-derived bioluminescent complexes | PROMEGA CORPORATION (US) | 2024-08-20 | — | — | US | disclosed |
| US-12060347-B2 | Bicyclic heteroaryl substituted compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-08-13 | — | — | US | disclosed |
| CN-118201920-A | PAPD5 inhibitors and methods of use thereof | 儿童医疗中心公司 | 2024-06-14 | — | — | CN | disclosed |
| EP-4140991-B1 | INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES | PROMEGA CORP (US) | 2024-05-15 | — | — | EP | disclosed |
| WO-2024086246-A2 | 2-SUBSTITUTED 3,4 A, 5, 7, 8, 8 A-HEXAHYDRO-4H-THIOP YRANO [4,3- DJPYRIMIDIN-4-ONES FOR WOUND TREATMENT | Eluciderm Inc. (US) | 2024-04-25 | — | — | WO | disclosed |
| WO-2024086246-A2 | 2-SUBSTITUTED 3,4 A, 5, 7, 8, 8 A-HEXAHYDRO-4H-THIOP YRANO [4,3- DJPYRIMIDIN-4-ONES FOR WOUND TREATMENT | Eluciderm Inc. (US) | 2024-04-25 | — | — | WO | disclosed |
| EP-1080069-A1 | ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-03-07 | — | — | EP | disclosed |
| CN-1268138-A | Compounds | ASTRA PHARMA PROD (GB) | 2000-09-27 | — | — | CN | disclosed |
| US-6083952-A | Compounds | ASTRA PHARMACEUTICALS LIMITED (GB) | 2000-07-04 | — | — | US | disclosed |
| EP-1000064-A1 | COMPOUNDS | AstraZeneca UK Limited (GB) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999054284-A1 | ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-28 | — | — | WO | disclosed |
| EP-0686625-B1 | ANTHRANILIC ACID DERIVATIVE | EISAI CO LTD (JP) | 1999-05-26 | — | — | EP | disclosed |
| WO-1999001455-A1 | COMPOUNDS | ASTRA PHARMACEUTICALS LTD. (GB) | 1999-01-14 | — | — | WO | disclosed |
| US-5716993-A | PHOSPHODIESTERASE ENZYME INHIBITOR FOR TREATING CARDIOVASCULAR DISORDER, ANGINA PECTORIS, HYPERTENSION, ASTHMA | EISAI CO., LTD. (JP) | 1998-02-10 | — | — | US | disclosed |
| CN-1118595-A | Anthranilic acid derivative | EISAI CO LTD (JP) | 1996-03-13 | — | — | CN | disclosed |
| EP-0686625-A1 | ANTHRANILIC ACID DERIVATIVE | Eisai Co., Ltd. (JP) | 1995-12-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12060347-B2 | Bicyclic heteroaryl substituted compounds | F2, F2RL3, F12 | ALDH1A1 1598/4885KDM4E 2420/4885GAA 4373/4885 |
| US-12065421-B2 | Inhibitors of oplophorus luciferase-derived bioluminescent complexes | LUC7L2, LYPLAL1, GUSB | ALDH1A1 1554/4885KDM4E 3154/4885GAA 937/4885 |
| US-20250026769-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | POT1, PARP15, TERT | ALDH1A1 2733/4885KDM4E 2544/4885GAA 2562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.